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In this issue of Annals of Surgical Oncology, Port
et al.1 present a well-designed prospective study of
18F-2-fluoro-2-deoxy-D-glucose positron emission
tomography (FDG-PET) scanning compared with
conventional imaging (body computed tomographic
[CT] scan plus bone scan) in women with breast
cancer. The overall ability to detect metastatic dis-
ease was equivalent for these two imaging strategies,
but patients undergoing PET scanning were less
likely to have false-positive findings that led to
additional diagnostic studies or procedures. These
data provide a very compelling argument in favor of
routinely performing PET scans in selected catego-
ries of patients with newly diagnosed breast cancer.
Indeed, the American College of Radiology Imaging
Network has included the study of functional
imaging as one component of their primary overall
research strategy for the remainder of this decade.2
It is essential to underscore a point made by Port
et al.1: the value of performing the metastatic screen
in a patient with newly diagnosed breast cancer is
relevant only for the patient with high-risk or ad-
vanced-stage disease; an asymptomatic patient with
clinically early-stage breast cancer will have only up
to a 5% likelihood of having a significant lesion
identified on metastatic work-up, whether conven-
tional imaging or PET scanning is used.3,4 The
Centers for Medicare and Medicaid Services ap-
proves coverage for PET scanning in women with
known advanced or metastatic disease, but not for
PET scanning performed at the initial diagnosis of
early breast cancer.5
As with any investigation that prompts a potential
change in practice patterns, the concept must be
scrutinized in the context of several other public
health-care issues:
1. Cost.
2. Patient satisfaction and tolerance.
3. Availability of technology.
4. Competing technology.
5. Downstream effects on other patient management
decisions.
6. Reproducibility of study results.
COST
The ‘‘conventional’’ metastatic imaging work-up
for an appropriately selected breast cancer patient
would include a chest radiograph, abdominal CT
scan, and bone scan, with cost estimates of $160,
$1500, and $1300, respectively. The cost of a total
body PET scan ranges $1,500$4,00.6 The few hun-
dred dollors in difference may appear scanty per
patient, but if multiplied over the approximately
20,000 stage III breast cancer patients diagnosed
annually7 that would require a metastatic surgery,
and the many more stage II breast cancer patients
that may undergo a preadjuvant therapy metastatic
screen, and if compounded by the expense of many
additional facilities having to purchase and maintain
new PET scan equipment, then the cost differential
becomes potentially more formidable.
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PATIENT SATISFACTION AND TOLERANCE
Both CT and PET necessitate an intravenous
injection and are therefore comparable in terms of
patient inconvenience and tolerance. The FDG
(a glucose analogue) requirement of PET, however,
requires that the procedure be coordinated appro-
priately with the medical needs of the diabetic pa-
tient. This risk may still balance out favorably
against the potential nephrotoxicity of CT contrast
agents.
AVAILABILITY OF TECHNOLOGY
Before any technology can be adopted as a new
standard of care, it should be readily available and
accessible to at least a reasonable proportion of the
breast cancer patient population. At this time, PET
scanning equipment is still costly and is available only
at selected medical facilities, estimated at approxi-
mately 200250 in the United States.6,8
COMPETING TECHNOLOGY
It can be argued that ‘‘plain’’ PET scans have
already been rendered obsolete by the combination
technology of CT-PET scans, which have the
advantage of offering improved morphological and
anatomical information in addition to the metabolic
clues. Body magnetic resonance imaging has also
become popular and is preferred over plain PET
scans by many radiologists because of their more
precise anatomical information. Also, alternatives
to the FDG label are being actively investigated for
improved cancer specificity and easier incorporation
into the treatment schedules of patients being fol-
lowed up for chemotherapy response in metastatic
lesions. Potential alternatives include 18F-fluoro-L-
thymidine, which can target DNA replication;
annexin V derivatives that can evaluate apoptosis;
and novel tracers that can specifically target estro-
gen receptors and HER-2/neu receptors.5 At pres-
ent, FDG-PET has limited value in the setting of
patients actively receiving chemotherapy, because
chemotherapy must be withheld for at least 3 weeks
before the study. Use of FDG-PET sooner can
yield a falsely negative result because metabolic
activity in a residual and viable tumor population is
paralyzed by the recent chemotherapy cycle.
DOWNSTREAM EFFECTS ON OTHER
PATIENT MANAGEMENT DECISIONS
The present study by Port et al.1 demonstrated a
minimal risk of PET-detected false positives that
would have generated ‘‘unnecessary’’ diagnostic
work-ups. However, it remains valid to question
whether widespread adoption of the PET scan as a
screen for metastatic disease might result in a decline
in its positive predictive value. Detection of indeter-
minate lesions on PET could result in referrals for
other interventions that will have associated costs and
risks. Furthermore, inaccurate interpretations of PET
findings could lead to inappropriate upstaging of a
patients disease, and this could result in the partic-
ularly hazardous scenario of missing an opportunity
to treat with curative intent.
REPRODUCIBILITY OF STUDY RESULTS
The Memorial Sloan-Kettering Cancer Center is
renowned for its multidisciplinary oncology expertise,
and this would certainly include the radiology staff. It
is not necessarily clear that other facilities are simi-
larly prepared to handle the workload of PET scan-
ning and PET interpretations.
The rapid evolution of technology makes it very
challenging to conduct prospective trials, which can
take several years to meet accrual goals, analyze re-
sults, and reach publication. Despite the concerns
raised, and in light of the difficulties faced by all clinical
trial investigators, Port et al.1 are to be heartily con-
gratulated for their strong results and clean study de-
sign. They have made a valuable contribution to our
understanding of the comparative value of FDG-PET
and conventional imaging techniques.
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